{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:55:55Z","timestamp":1792068955806,"version":"4.4.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ejpb.2015.02.015","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T04:35:10Z","timestamp":1424406910000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Transdermal delivery of testosterone"],"prefix":"10.1016","volume":"92","author":[{"given":"Jonathan","family":"Hadgraft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majella E.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.02.015_b0005","first-page":"28","article-title":"Guidelines on male hypogonadism","author":"Dohle","year":"2012","journal-title":"Eur. Assoc. Urol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jc.2009-2354","article-title":"Task force, endocrine society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0015","first-page":"625434","article-title":"Hypogonadism in the aging male diagnosis, potential benefits and risks of testosterone replacement therapy","author":"Surampudi","year":"2012","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0020","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0140-6736(00)85865-1","article-title":"Percutaneous absorption of male hormone","volume":"232","author":"Foss","year":"1938","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.02.015_b0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1210\/jcem-27-5-686","volume":"27","author":"Southren","year":"1967","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1210\/jcem-67-1-104","article-title":"Quantitating genetic and nongenetic factors influencing androgen production and clearance rates in men","volume":"67","author":"Meikle","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0350","unstructured":"A.C. Moffat, D.M. Osselton, B. Widdop, J. Watts (Eds.), Testosterone, Clarke\u2019s Analysis of Drugs and Poisons, Fourth ed., Pharmaceutical Press, 2004."},{"key":"10.1016\/j.ejpb.2015.02.015_b0040","first-page":"719","article-title":"Effect of polyoxyethylene glycols (PEG) on properties of the matrix model of transdermal therapeutic system (TTS) with testosterone","volume":"46","author":"Cichon","year":"1991","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2015.02.015_b0045","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI103389","article-title":"Metabolism of 4-C14-testosterone in human subjects. I. Distribution in bile, blood, feces and urine","volume":"35","author":"Sandberg","year":"1956","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2015.02.015_b0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1210\/jcem-38-3-424","article-title":"Metabolism of testosterone-1,2-3H in man. Distribution of the major 17-ketosteroid metabolites in plasma: relation to thyroid states","volume":"38","author":"Hellman","year":"1974","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0055","first-page":"3822","article-title":"AHFS drug information","author":"Testosterone","year":"2015","journal-title":"ASHP"},{"key":"10.1016\/j.ejpb.2015.02.015_b0060","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1210\/jc.2003-031802","article-title":"Testosterone metabolic clearance and production rates determined by stable isotope dilution\/tandem mass spectrometry in normal men: influence of ethnicity and age","volume":"89","author":"Wang","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1152\/physrev.1973.53.2.496","article-title":"Metabolism of hormones, drugs and other substances by the gut","volume":"53","author":"Hartiata","year":"1973","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejpb.2015.02.015_b0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.me.35.020184.001231","article-title":"Clinical use of androgens","volume":"35","author":"Synder","year":"1984","journal-title":"Ann. Rev. Med."},{"key":"10.1016\/j.ejpb.2015.02.015_b0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1210\/jcem-61-4-705","article-title":"Bioavailability of albumin-boundtestosterone","volume":"61","author":"Manni","year":"1985","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0300-595X(86)80024-X","article-title":"Serum bioavailability of sex steroid hormones","volume":"15","author":"Pardridge","year":"1986","journal-title":"Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0085","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1373\/clinchem.2007.101303","article-title":"Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence","volume":"54","author":"Swerdloff","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejpb.2015.02.015_b0090","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1523-1747.2002.00613.x","article-title":"Cutaneous androgen metabolism: basic research and clinical perspectives","volume":"119","author":"Chen","year":"2002","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1172\/JCI105994","article-title":"The conversion of testosterone to 5 alpha-androstan-17boI-3-one (dihydrotestosterone) by skin slices of man","volume":"48","author":"Wilson","year":"1969","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejpb.2015.02.015_b0100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(86)90600-8","article-title":"Transdermal testosterone substitution therapy for male hypogonadism","volume":"2","author":"Bals-Pratsch","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.02.015_b0105","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1210\/jcem-66-3-546","article-title":"Transdermal testosterone therapy in the treatment of male hypogonadism","volume":"66","author":"Ahmed","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0002-9343(87)90757-1","article-title":"Androgen therapy of hypogonadal men with transscrotal testosterone systems","volume":"83","author":"Korenman","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejpb.2015.02.015_b0115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1210\/jcem-41-4-793","article-title":"Altered blood androgens in elderly men with prostate hyperplasia","volume":"41","author":"Horton","year":"1975","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0120","first-page":"163","article-title":"Percutaneous absorption in aged skin","volume":"vol. 6","author":"Christophers","year":"1965"},{"key":"10.1016\/j.ejpb.2015.02.015_b0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/BF01062121","article-title":"The effect of aging on percutaneous absorption in man","volume":"17","author":"Roskos","year":"1989","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejpb.2015.02.015_b0130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archderm.1966.01600290123023","article-title":"Percutaneous penetration of 14C hydrocortisone in man. II. Effect of certain bases and pretreatments","volume":"94","author":"Feldmann","year":"1966","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0135","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1749-6632.1967.tb34906.x","article-title":"The effect of DMSO on percutaneous penetration of hydrocortisone and testosterone in man","volume":"141","author":"Maibach","year":"1967","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.ejpb.2015.02.015_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/jid.1969.12","article-title":"Percutaneous penetration of steroids in man","volume":"52","author":"Feldmann","year":"1969","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0010-7824(79)90095-7","article-title":"Contraceptionvia topical application? \u2013 a review","volume":"20","author":"Schaefer","year":"1979","journal-title":"Contraception"},{"key":"10.1016\/j.ejpb.2015.02.015_b0150","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jps.2600741218","article-title":"Percutaneous absorption of steroids: effect of repeated application","volume":"74","author":"Bucks","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.02.015_b0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1523-1747.ep12463284","article-title":"Bioavailability of topically administered steroids: a \u201cmass balance\u201d technique","volume":"91","author":"Bucks","year":"1988","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1210\/jcem-68-2-369","article-title":"Treatment of primary hypogonadism in men by the transdermal administration oftestosterone","volume":"68","author":"Findlay","year":"1989","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/jcem-64-2-266","article-title":"Transdermal delivery of testosterone","volume":"64","author":"Findlay","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0090-4295(91)80289-J","article-title":"Hypogonadal impotence treated by transdermal testosterone","volume":"37","author":"McClure","year":"1991","journal-title":"Urology"},{"key":"10.1016\/j.ejpb.2015.02.015_b0175","unstructured":"Anonymous. Testosterone patches for hypogonadism. Medical Letter on Drugs and Therapeutics. 38 (1996) 49\u201350."},{"key":"10.1016\/j.ejpb.2015.02.015_b0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0168-3659(92)90089-A","article-title":"Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men","volume":"19","author":"Mazer","year":"1992","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejpb.2015.02.015_b0185","first-page":"623","article-title":"Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men","volume":"74","author":"Meikle","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0190","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/S0022-5347(01)66141-X","article-title":"Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system","volume":"155","author":"Arver","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0195","first-page":"1832","article-title":"Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site \u2013 a clinical research center study","volume":"81","author":"Meikle","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0200","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/j.1552-4604.1997.tb04298.x","article-title":"Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men","volume":"37","author":"Yu","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0205","unstructured":"Auxilium Pharmaceuticals Inc., United States Securities and Exchange Commission. Form 10K. 198p."},{"key":"10.1016\/j.ejpb.2015.02.015_b0210","first-page":"964","article-title":"Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study","volume":"85","author":"Wang","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0215","first-page":"4500","article-title":"Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men","volume":"85","author":"Swerdloff","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0220","first-page":"2839","article-title":"Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men","volume":"85","author":"Wang","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0225","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/713604792","article-title":"Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel","volume":"6","author":"Swerdloff","year":"2003","journal-title":"Aging Male"},{"key":"10.1016\/j.ejpb.2015.02.015_b0230","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1210\/jc.2003-032006","article-title":"Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men","volume":"89","author":"Wang","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/bdd.345","article-title":"Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel","volume":"24","author":"Marbury","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejpb.2015.02.015_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1464-410X.2003.04016.x","article-title":"A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function","volume":"91","author":"McNicholas","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.ejpb.2015.02.015_b0245","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2002-021058","article-title":"North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function","volume":"88","author":"Steidle","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0250","first-page":"87","article-title":"Long-term effects of testim(r) 1% testosterone gel in hypogonadal men","volume":"7","author":"Dean","year":"2005","journal-title":"Rev. Urol."},{"key":"10.1016\/j.ejpb.2015.02.015_b0255","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2164\/jandrol.111.014308","article-title":"A novel testosterone 2% gel for the treatment of hypogonadal males","volume":"33","author":"Dobs","year":"2012","journal-title":"J. Androl."},{"key":"10.1016\/j.ejpb.2015.02.015_b0260","doi-asserted-by":"crossref","unstructured":"A. Morgentaler, J. McGettigan, Q. Xiang, T.M. Danoff, E.M. Gould, Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial, Int. J. Impot. Res. 2014, in press. doi: 10.1038\/ijir.2014.28.","DOI":"10.1038\/ijir.2014.28"},{"key":"10.1016\/j.ejpb.2015.02.015_b0265","unstructured":"<www.vogelxo.com> (accessed December 2014)."},{"key":"10.1016\/j.ejpb.2015.02.015_b0270","unstructured":"FDA Drug Safety Newsletter. Postmarket Reviews. 2 (2009)."},{"key":"10.1016\/j.ejpb.2015.02.015_b0275","unstructured":"US FDA. Draft guidance on testosterone (2013)."},{"key":"10.1016\/j.ejpb.2015.02.015_b0280","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2265.2011.04152.x","article-title":"Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men","volume":"75","author":"Wang","year":"2011","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.ejpb.2015.02.015_b0285","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/03007995.2012.681034","article-title":"Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men","volume":"28","author":"Muram","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejpb.2015.02.015_b0290","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2015.02.015_b0295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.02.015_b0300","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2015.02.015_b0305","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone therapy and cardiovascular events among men; a systematic review and metaanalysis of placebo-controlled randomized trials","volume":"11","author":"Xu","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.ejpb.2015.02.015_b0310","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.02.015_b0315","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","article-title":"Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis","volume":"13","author":"Corona","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejpb.2015.02.015_b0320","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-014-0211-5","article-title":"Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis","volume":"12","author":"Borst","year":"2014","journal-title":"BMC Med."},{"key":"10.1016\/j.ejpb.2015.02.015_b0325","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/1965869","article-title":"Current efforts to develop male hormonal contraception","volume":"9","author":"Schearer","year":"1978","journal-title":"Stud. Fam. Plan."},{"key":"10.1016\/j.ejpb.2015.02.015_b0330","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0010-7824(78)90045-8","article-title":"Clinical trial with testosterone undecanoate for male fertility control","volume":"18","author":"Nieschlag","year":"1978","journal-title":"Contraception"},{"key":"10.1016\/j.ejpb.2015.02.015_b0335","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1210\/jc.2006-1411","article-title":"Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist","volume":"91","author":"Page","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0340","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2008-2604","article-title":"Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men","volume":"94","author":"Mahabadi","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejpb.2015.02.015_b0345","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1210\/jc.2012-1384","article-title":"A new combination of testosterone and nestorone transdermal gels for male hormonal contraception","volume":"97","author":"Ilani","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115000971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115000971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T23:29:03Z","timestamp":1566343743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115000971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":69,"alternative-id":["S0939641115000971"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.02.015","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transdermal delivery of testosterone","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}